<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952688</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01178-31</org_study_id>
    <nct_id>NCT04952688</nct_id>
  </id_info>
  <brief_title>Modifications in Retinal Microvascularization With Targeted Anti-angiogenic Therapy in Colorectal Cancer</brief_title>
  <acronym>VOCANGIO</acronym>
  <official_title>Modifications in Retinal Microvascularization With OCT- Angiography in Patients With First-line Colorectal Cancer, Treated With Targeted Anti-angiogenic Therapy.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Georges Francois Leclerc</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Georges Francois Leclerc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Retinal microvascularization can provide important informations to systemic vascular&#xD;
      phenomena. The non-invasive quantitative description of the retinal vascularization is now&#xD;
      possible by performing OCT-angiography and their image analysis software (vascular density&#xD;
      and retinal perfusion). Systemic microvacular changes during the establishment of oncological&#xD;
      treatment by targeted antiangiogenic therapy are little described in the literature. The&#xD;
      objective of this pilot study is to describe the evolution of the retinal vascular density of&#xD;
      patients with antiangiogenic drugs. In addition, the evolution of the retinal vascular&#xD;
      density of patients on antiangiogenic drugs will study as a function of the response to the&#xD;
      treatment and the toxicity of these treatments.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to describe the change in retinal vascular density of&#xD;
      patients with first-line colorectal cancer treated with Bevacizumab.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 14, 2020</start_date>
  <completion_date type="Anticipated">July 14, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 14, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>retinal vascular density retinal vascular density</measure>
    <time_frame>12 month</time_frame>
    <description>this measurement will be the average of the 4 quadrants (temporal, nasal, superior and inferior 24). It will be performed by PLEX Elite 9000 Swept Source OCT-A before, during and at the end of the anti-angiogenic treatment</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inclusion&#xD;
Before Anti-VEGF treatment: opht</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>OCT- Angiographie</intervention_name>
    <description>Ophthalmological examinations</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient over 18 years old starting first-line treatment for metastatic colorectal&#xD;
             cancer including BEVACIZUMAB (AVASTIN®)&#xD;
&#xD;
          2. Systemic or intraocular anti-VEGF treatment naïve&#xD;
&#xD;
          3. ECOG ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant woman,&#xD;
&#xD;
          2. Minor patient or under legal protection&#xD;
&#xD;
          3. Person deprived of liberty or under guardianship&#xD;
&#xD;
          4. Inability to undergo medical monitoring of the trial&#xD;
&#xD;
          5. Impossibility of carrying out the OCT-A&#xD;
&#xD;
          6. Patient with a contraindication to Tropicamide 0.5% eye drops&#xD;
&#xD;
          7. Patient with a history of degenerative macular pathology, vascular macular pathology&#xD;
             or presenting an epiretinal membrane with traction phenomenon.&#xD;
&#xD;
          8. Diabetes&#xD;
&#xD;
          9. Patient for whom it is not possible to schedule an ophthalmology consultation before&#xD;
             the start of treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Audrey HENNEQUIN</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Georges François Leclerc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Audrey HENNEQUIN</last_name>
    <phone>03 80 73 75 06</phone>
    <email>ahennequin@cgfl.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Audrey HENNEQUIN</last_name>
      <phone>03 80 73 75 06</phone>
      <email>ahennequin@cgfl.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine DROUILLARD</last_name>
      <email>antoine.drouillard@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 18, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>July 2, 2021</last_update_submitted>
  <last_update_submitted_qc>July 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>retina</keyword>
  <keyword>OCT-angiography</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>microvascularization</keyword>
  <keyword>Targeted therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

